Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Behandeling van anale HSIL verlaagt risico anuscarcinoom
aug 2022 | HIV, Maag-darm-leveroncologie, Virale infecties